Patents by Inventor Arwed Cleve
Arwed Cleve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230250104Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: ApplicationFiled: September 14, 2022Publication date: August 10, 2023Inventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye
-
Patent number: 11524938Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.Type: GrantFiled: October 9, 2020Date of Patent: December 13, 2022Assignee: Bayer Pharma AktiengesellschaftInventors: Stefan Werner, Stefanie Mesch, Arwed Cleve, Nico Bräuer, Simon Anthony Herbert, Markus Koch, Henrik Dahllöf, Maren Osmers, Elizabeth Hardaker, Anton Lishchynskyi
-
Publication number: 20220324807Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.Type: ApplicationFiled: October 9, 2020Publication date: October 13, 2022Applicant: Bayer Pharma AktiengesellschaftInventors: Stefan WERNER, Stefanie MESCH, Arwed CLEVE, Nico BRÄUER, Simon Anthony HERBERT, Markus KOCH, Henrik DAHLLÖF, Maren OSMERS, Elizabeth HARDAKER, Anton LISHCHYNSKYI
-
Patent number: 11267819Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: GrantFiled: January 9, 2020Date of Patent: March 8, 2022Assignee: Celltaxsis, LLCInventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye
-
Patent number: 10844016Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.Type: GrantFiled: April 26, 2017Date of Patent: November 24, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Stefan Werner, Stefanie Mesch, Arwed Cleve, Nico Bräuer, Simon Anthony Herbert, Markus Koch, Henrik Dahllöf, Maren Osmers, Elizabeth Hardaker, Anton Lishchynskyi
-
Publication number: 20200308181Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: ApplicationFiled: January 9, 2020Publication date: October 1, 2020Inventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye
-
Patent number: 10350206Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.Type: GrantFiled: September 17, 2015Date of Patent: July 16, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Anne Mengel, Hans-Georg Lerchen, Manfred Möwes, Thomas Müller, Lars Bärfacker, Marion Hitchcock, Arwed Cleve, Joachim Kuhnke, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Ursula Mönning, Simon Holton
-
Publication number: 20190119210Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.Type: ApplicationFiled: April 26, 2017Publication date: April 25, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Stefan WERNER, Stefanie MESCH, Arwed CLEVE, Nico BRÄUER, Simon Anthony HERBERT, Markus KOCH, Henrik DAHLLÖF, Maren OSMERS, Elizabeth HARDAKER, Anton LISHCHYNSKYI
-
Publication number: 20180230159Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: ApplicationFiled: February 8, 2018Publication date: August 16, 2018Inventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye
-
Patent number: 9890147Abstract: What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.Type: GrantFiled: August 13, 2013Date of Patent: February 13, 2018Assignee: Bayer Pharma AktiengesellshaftInventors: Stephan Siegel, Stefan Bäurle, Arwed Cleve, Bernard Haendler, Amaury Ernesto Fernandez-Montalvan, Ursula Mönning, Sabine Krause, Pascale Lejeune, Norbert Schmees, Matthias Busemann, Simon Holton, Joachim Kuhnke
-
Publication number: 20170305882Abstract: Compounds of formula (I) and their use as pharmaceuticals.Type: ApplicationFiled: September 17, 2015Publication date: October 26, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Anne MENGEL, Hans-Georg LERCHEN, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNÁNDEZ-MONTÁLVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
-
Publication number: 20170275270Abstract: Compounds of formula (I) and their use as pharmaceuticals.Type: ApplicationFiled: September 15, 2015Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Lars BÄRFACKER, Thomas MÜLLER, Anne MENGEL, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING
-
Publication number: 20170275269Abstract: Compounds of formula (I) and their use as pharmaceuticals.Type: ApplicationFiled: September 17, 2015Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Anne MENGEL, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING
-
Publication number: 20170273980Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.Type: ApplicationFiled: September 17, 2015Publication date: September 28, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Anne MENGEL, Hans-Georg LERCHEN, Manfred MÖWES, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Joachim KUHNKE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
-
Publication number: 20170226081Abstract: The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: July 22, 2015Publication date: August 10, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Bernd BUCHMANN, Iring HEISLER, Thomas MÜLLER, Arwed CLEVE, Mélanie HÉROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
-
Publication number: 20170210738Abstract: The present invention relates to chemical compounds of formula (I) that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: July 22, 2015Publication date: July 27, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Bernd BUCHMANN, Iring HEISLER, Thomas MÜLLER, Arwed CLEVE, Melanie HEROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
-
Publication number: 20170037028Abstract: The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.Type: ApplicationFiled: December 16, 2014Publication date: February 9, 2017Inventors: Iring HEISLER, Thomas MÜLLER, Holger SIEBENEICHER, Bernd BUCHMANN, Arwed CLEVE, Judith GÜNTHER, Marcus KOPPITZ, Melanie HEROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
-
Publication number: 20160272649Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: ApplicationFiled: March 14, 2016Publication date: September 22, 2016Inventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye
-
Publication number: 20160129011Abstract: BET-protein-inhibitory, in particular BRD4-inhibitory bicyclo- and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), pharmaceutical compositions comprising the compounds according to the invention, and the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders, are described. Furthermore, the use of BET protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control is described.Type: ApplicationFiled: February 17, 2014Publication date: May 12, 2016Inventors: Stephan SIEGEL, Stefan BÄURLE, Arwed CLEVE, Bernard HAENDLER, Amaury Ernesto FERNÁNDEZ-MONTALVÁN, Ursula MÖNNING, Sabine KRAUSE, Pascale LEJEUNE, Matthias BUSEMANN, Joachim KUHNKE
-
Patent number: 9315509Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: GrantFiled: June 24, 2014Date of Patent: April 19, 2016Assignee: Celtaxsys, Inc.Inventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye